The Street’s Key Stock Analysts Research Reports

$AMG, $ALXM, $BMRN, $BIIB, $CNMD, $CRSP, $OII, $VRTX

Daily HeffX-LTN reviews dozens of  the Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers.

Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of stocks analysts have singled out to look at carefully Wednesday, as follows:

Amgen Inc. (NASDAQ:AMGN) was started as Buy with a 256 target price at SunTrust Robinson Humphrey.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was started with a Buy rating and a 225 target price at SunTrust Robinson Humphrey.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was started with a Buy rating and a 110 target price at SunTrust Robinson Humphrey.

Biogen Inc. (NASDAQ:BIIB) was started with a Buy rating and a 337 target price at SunTrust Robinson Humphrey.

CONMED Corp. (NASDAQ:CNMD) was started as Overweight with a $136 target price at JPMorgan.

CRISPR Therapeutics A.G. (NASDAQ:CRSP) was raised to Outperform from Perform with a 65 target price at Oppenheimer.

Oceaneering International Inc. (NYSE:OII) was started as Buy and a 17 price objective at Merrill Lynch.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) was started with a Buy rating and a 235 target price at SunTrust Robinson Humphrey.

Stay tuned…

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :  
CONNECT WITH